Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Minority Interest (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Minority Interest data on record, last reported at $160.3 million in Q4 2025.

  • For Q4 2025, Minority Interest fell 36.36% year-over-year to $160.3 million; the TTM value through Dec 2025 reached $160.3 million, down 36.36%, while the annual FY2025 figure was $160.3 million, 36.36% down from the prior year.
  • Minority Interest reached $160.3 million in Q4 2025 per MRVI's latest filing, down from $186.4 million in the prior quarter.
  • Across five years, Minority Interest topped out at $379.1 million in Q1 2023 and bottomed at $99.7 million in Q1 2021.
  • Average Minority Interest over 5 years is $270.9 million, with a median of $269.8 million recorded in 2022.
  • Peak YoY movement for Minority Interest: surged 247.04% in 2021, then crashed 40.46% in 2025.
  • A 5-year view of Minority Interest shows it stood at $229.9 million in 2021, then soared by 56.63% to $360.0 million in 2022, then increased by 3.64% to $373.1 million in 2023, then crashed by 32.49% to $251.9 million in 2024, then plummeted by 36.36% to $160.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Minority Interest were $160.3 million in Q4 2025, $186.4 million in Q3 2025, and $202.1 million in Q2 2025.